Shattuck Labs, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2026-10: Study NCT07753850; Company role Lead sponsor; Phase Phase 2; Status Not yet recruiting.
- 2025-09-18: Study NCT07158437; Company role Lead sponsor; Phase Phase 1; Status Active not recruiting.
- 2022-08-18: Study NCT05483933; Company role Lead sponsor; Phase Phase 1; Status Completed.
- 2022-03-17: Study NCT05275439; Company role Lead sponsor; Phase Phase 1; Status Terminated.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2026-10 | NCT07753850 A Study of SL-325 in Crohn's Disease Patients | Lead sponsor | Phase 2 | Not yet recruiting | Crohn's Disease | 232 | 2030-06 |
| 2025-09-18 | NCT07158437 Phase 1 Study of SL-325 in Healthy Volunteers | Lead sponsor | Phase 1 | Active not recruiting | Healthy Volunteers | 72 | 2026-07 |
| 2022-08-18 | NCT05483933 Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers | Lead sponsor | Phase 1 | Completed Results posted | Platinum-resistant Ovarian Cancer; Fallopian Tube Cancer; Epithelial Ovarian Cancer; Ovarian Cancer; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Primary Peritoneal Carcinoma | 86 | 2025-02-07 |
| 2022-03-17 | NCT05275439 Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML | Lead sponsor | Phase 1 | Terminated Results posted | Acute Myeloid Leukemia; Myelodysplastic Syndromes | 106 | 2025-02-06 |
| 2020-09-17 | NCT04502888 Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin | Lead sponsor | Phase 1 | Terminated Results posted | Cutaneous Squamous Cell Carcinoma; Squamous Cell Carcinoma of Head and Neck | 5 | 2022-04-08 |
| 2020-06-29 | NCT04406623 Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer | Lead sponsor | Phase 1 | Completed Results posted | Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma | 27 | 2023-02-02 |
| 2019-03-26 | NCT03894618 SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | Lead sponsor | Phase 1 | Completed Results posted | Squamous Cell Carcinoma of the Head and Neck; Melanoma; Non Small Cell Lung Cancer; Urothelial Carcinoma; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Squamous Cell Carcinoma of the Anus; Squamous Cell Carcinoma of the Cervix; Squamous Cell Carcinoma of the Skin; Renal Cell Carcinoma; Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma; Mismatch Repair Deficient or MSI-High Solid Tumors | 49 | 2023-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |